Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0453400
Funder
Australian Research Council
Funding Amount
$110,040.00
Summary
The Roboocyte™: a medium-throughput, secondary functional, screening facility. Changes in ion channel function have been implicated in a wide variety of human diseases. For this reason many researchers are studying ion channels to understand how they work and how they can develop new drug treatments. The slowest step in evaluating the biological activity of compounds is testing them against the ion channels and the current technology requires much tedious manual handling and extensive operator e ....The Roboocyte™: a medium-throughput, secondary functional, screening facility. Changes in ion channel function have been implicated in a wide variety of human diseases. For this reason many researchers are studying ion channels to understand how they work and how they can develop new drug treatments. The slowest step in evaluating the biological activity of compounds is testing them against the ion channels and the current technology requires much tedious manual handling and extensive operator expertise. The Roboocyte facility will triple testing productivity by allowing for the rapid and automated screening of large libraries of compounds. Such a facility will be unique to the Southern Hemisphere.Read moreRead less
Streamlining the dynamin epilepsy drug pipeline. Epilepsy affects up to one percent of Australia's population, yet one in three fail to respond to current medications. Our results will greatly impact on development of future epilepsy therapy. Identification of a new target for epileptic will allow better drug design to improve the potency of our lead drugs. This holds hope that new generation drugs will be more effective. The drugs are predicted to have fewer complications and side-effects. Th ....Streamlining the dynamin epilepsy drug pipeline. Epilepsy affects up to one percent of Australia's population, yet one in three fail to respond to current medications. Our results will greatly impact on development of future epilepsy therapy. Identification of a new target for epileptic will allow better drug design to improve the potency of our lead drugs. This holds hope that new generation drugs will be more effective. The drugs are predicted to have fewer complications and side-effects. The outcome has the potential to vastly improve prospects for up to 200,000 Australians. Intellectual property (IP) retained in Australia will generate future biotechnology industry. The novel chemical biological approaches will facilitate training of future generations of Australian scientists.Read moreRead less